1018-00007 · Penterra Pharmaceuticals Corp · Post-Judgment

matter-closing-memo.docx DOCUMENT Litigation

29 / 35 ← → ✕

Contract analysis Extract to table

MEMORANDUM — PRIVILEGED & CONFIDENTIAL

ATTORNEY WORK PRODUCT

FROM: Hannah Brinkley, Lead Associate, Litigation

TO: Linda Osei, Responsible Partner, Litigation

CC: Priya Anand, Billing Partner; Patrick Gallagher, Working Associate

DATE: September 12, 2022

RE: Matter Closing Memorandum — Penterra Pharmaceuticals Corp. v. Vantage Medical Distribution, LLC, Docket No. 2184-CV-01537-BLS (MA Superior Court, Business Litigation Session, Suffolk County)

MATTER NO.: 1018-00007

CLIENT: Penterra Pharmaceuticals Corp.

This memorandum is protected by the attorney-client privilege and the work product doctrine. It is intended solely for internal use by attorneys and staff of Calderwood & Harkness LLP involved in the above-referenced matter. This memorandum should not be distributed to the client or any third party without prior written approval of the Responsible Partner. Unauthorized disclosure may result in waiver of applicable privileges.

I. PURPOSE OF MEMORANDUM

This memorandum serves as the formal matter closing record for Calderwood & Harkness LLP's ("C&H" or the "Firm") representation of Penterra Pharmaceuticals Corp. ("Penterra" or the "Client") in its declaratory-judgment action against Vantage Medical Distribution, LLC ("Vantage"), captioned Penterra Pharmaceuticals Corp. v. Vantage Medical Distribution, LLC, Docket No. 2184-CV-01537-BLS, in the Massachusetts Superior Court, Business Litigation Session, Suffolk County.

The purpose of this memorandum is to provide a comprehensive record of the engagement, the litigation, and the resolution for the Firm's files. Specifically, this memorandum summarizes: (a) the engagement and matter background, including the identities and roles of all key participants; (b) the key procedural history of the litigation from inception through final judgment; (c) the substantive outcome of the case, including a detailed analysis of the court's Memorandum of Decision and Order; (d) a financial summary of professional fees and costs billed to the Client; (e) key lessons learned from the engagement that may be of use to the Firm in future matters; and (f) recommendations for file retention, administrative closing, and potential future matters.

As an important threshold matter, this memorandum confirms that all appeal deadlines have expired. The Final Judgment was entered on August 5, 2022. Under Massachusetts Rules of Appellate Procedure, Rule 4(a), the thirty-day appeal period ran through September 4, 2022. As of the date of this memorandum, Vantage has not filed a notice of appeal, and the appeal deadline has passed. The matter is therefore fully concluded, and no further proceedings are anticipated.

II. ENGAGEMENT SUMMARY

A. Client and Engagement Team

Client. Penterra Pharmaceuticals Corp. is a Delaware corporation, publicly traded on the Nasdaq Global Select Market under the ticker symbol "PTRA," with its principal executive offices located at 400 Carnegie Center Drive, Suite 600, Princeton, New Jersey 08540. Penterra is a mid-cap specialty pharmaceutical company focused on oncology, rare diseases, and immunology therapeutics.

Client Contacts. The following individuals served as the primary client contacts throughout the engagement:

• Jennifer Chao, Esq. — General Counsel. Ms. Chao served as the day-to-day client contact and primary liaison between Penterra and C&H. She coordinated document collection, facilitated internal communications regarding the litigation, and provided strategic input throughout the engagement. Ms. Chao was the signatory on the engagement letter on behalf of Penterra.

• Steven Kapoor — Vice President, Commercial Operations. Mr. Kapoor was a central fact witness in the litigation, as the author of the January 12, 2018 email to Donald Farnham that became the factual centerpiece of the dispute. Mr. Kapoor was deposed on November 2, 2021, and provided an affidavit in support of Penterra's motion for summary judgment. He participated actively in litigation strategy discussions relating to the commercial context of the EDA.

• Rachel Mendez — Director of Distribution & Logistics. Ms. Mendez provided testimony regarding Penterra's distribution logistics framework and the internal systems governing product shipments to authorized distributors. She was deposed on November 19, 2021, and provided an affidavit in support of summary judgment.

• Dr. Marcus Lindholm — Chief Executive Officer. Dr. Lindholm was involved in high-level strategic decisions regarding the litigation, including the initial decision to pursue a declaratory-judgment action and the assessment of settlement posture at key milestones. Dr. Lindholm participated in periodic status calls but was not a fact witness in the proceedings.

Engagement Letter. The engagement letter was executed on March 29, 2021, following completion of the Firm's conflict-of-interest check, which was cleared on March 26, 2021. The engagement letter established the scope of representation as the prosecution of a declaratory-judgment action and defense against any counterclaims asserted by Vantage in connection with the parties' Exclusive Distribution Agreement.

Matter Number. The Firm assigned matter number 1018-00007 to this engagement.

Engagement Team. The following C&H attorneys comprised the core engagement team:

In addition to the core team, the Firm utilized its internal litigation support department for document management and production, and its e-discovery team for processing and reviewing electronically stored information collected from Penterra's custodians.

B. Fee Arrangement

The engagement was structured on an hourly billing basis at C&H's standard rates, subject to a seven percent (7%) discount reflecting the Firm's longstanding relationship with Penterra. Penterra has been a client of C&H since 2015, and the discounted rate structure has been applied to all Penterra engagements during that period.

The applicable billing rates were as follows:

At the outset of the engagement, the Firm provided Penterra with an estimated budget range of $750,000 to $1,200,000 for the matter, assuming the case proceeded through trial. This estimate was communicated to Ms. Chao in a budget memorandum attached to the engagement letter and was acknowledged by the Client. As discussed in Section VI below, the actual total billed came in below the midpoint of this estimated range, principally because the matter was resolved on summary judgment without the need for trial.

C. Adverse Party and Opposing Counsel

Defendant. Vantage Medical Distribution, LLC is a Massachusetts limited liability company organized under the laws of the Commonwealth of Massachusetts, with its principal place of business at 75 Cabot Road, Suite 310, Medford, Massachusetts 02155. Vantage was founded in 2009 by Donald R. Farnham, who serves as its Managing Member and Chief Executive Officer. Vantage is a regional specialty pharmaceutical distributor focusing on hospital and clinic-based oncology and immunology products in the northeastern United States.

Opposing Counsel. Vantage was represented throughout the litigation by Hargrove, Sinclair & Polk LLP ("HSP"), a mid-size New England litigation boutique specializing in distribution, franchise, and dealer-protection disputes. HSP's offices are located at 200 Ashbury Asset Advisors, Suite 1800, Boston, Massachusetts 02109. The lead partner on the matter was Kenneth M. Rourke, and the associate counsel was Alicia Fontaine. Mr. Rourke and Ms. Fontaine handled all aspects of the litigation on Vantage's behalf, including the filing and prosecution of Vantage's counterclaims and cross-motion for summary judgment.

HSP is well-regarded in the Boston legal community for its representation of distributors and franchisees in disputes with principals and manufacturers. Mr. Rourke in particular has significant experience litigating territory exclusivity issues and dealer-protection claims under Massachusetts law. The quality of opposing counsel underscored the importance of thorough preparation and precise legal analysis throughout the engagement.

III. MATTER BACKGROUND AND FACTUAL SUMMARY

A. The Parties' Relationship

Penterra Pharmaceuticals Corp. is a mid-cap specialty pharmaceutical company with consolidated revenue of approximately $1.87 billion for fiscal year 2021. Penterra's product portfolio is concentrated in three therapeutic areas: oncology, rare diseases, and immunology. The company maintains a diversified distribution network across the United States, utilizing a combination of specialty distributors and direct-to-institution channels depending on the product line and geographic region.

Penterra's flagship oncology product is Oncalaris® (pegvisomant-axel), a next-generation pegylated enzyme therapy indicated for the treatment of refractory colorectal cancer. Oncalaris® was first launched commercially in 2016 and has achieved significant market penetration in the oncology space. For fiscal year 2021, Oncalaris® generated approximately $412 million in net revenue, representing approximately 22% of Penterra's total consolidated revenue. The product's commercial success has been supported by robust clinical data and a growing body of real-world evidence demonstrating improved progression-free survival outcomes in patients with refractory disease.

Vantage Medical Distribution, LLC was founded in 2009 by Donald R. Farnham and operates as a regional specialty pharmaceutical distributor serving hospitals, cancer centers, and oncology clinics in the northeastern United States. Vantage reported total revenue of approximately $148 million for fiscal year 2021. Critically, Penterra products — principally Oncalaris® and, to a lesser extent, Renuvesta® (cilosporin-beta) — accounted for approximately $67 million of Vantage's fiscal year 2021 revenue, representing approximately 45.3% of Vantage's total revenue. This substantial revenue concentration underscored the commercial significance of the distribution relationship to Vantage and provided important context for understanding Vantage's aggressive litigation posture throughout the case.

B. The Exclusive Distribution Agreement

The foundational contract governing the parties' relationship was the Exclusive Distribution Agreement (the "EDA"), executed with an effective date of July 1, 2017. The key provisions of the EDA relevant to the dispute are summarized below.

Term and Renewal. The EDA provided for an initial term of five (5) years, expiring on June 30, 2022, with two successive one-year automatic renewal options. Non-renewal required one hundred eighty (180) days' prior written notice by either party.

Products Covered. The EDA covered the following Penterra products: (i) Oncalaris® (pegvisomant-axel) in 20 mg and 40 mg vial presentations; and (ii) Renuvesta® (cilosporin-beta) in 5 mg capsule presentation.

Grant of Exclusivity (Section 2.1). Section 2.1 of the EDA provided that "Supplier hereby grants to Distributor the exclusive right to distribute the Products within the Territory, as defined in Exhibit A attached hereto and incorporated herein by reference."

Territory Definition (Exhibit A). Exhibit A to the EDA defined the "Territory" as the following six states: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont (collectively, the "New England States"). Exhibit A was a stand-alone schedule that listed these six states by name. It contained no reference to any other states or geographic regions, and no catch-all or expansion language.

Limitation on Extra-Territorial Activity (Section 2.3). Section 2.3 provided: "Distributor shall not actively solicit orders for, or deliver, Products to customers located outside the Territory without the prior written consent of Supplier." This provision expressly conditioned any extra-territorial distribution on Penterra's prior written consent — a requirement that would prove dispositive in the litigation.

Minimum Purchase Commitment (Section 5.2). Section 5.2 required Vantage to purchase a minimum of $9.5 million per year of Oncalaris® at wholesale acquisition cost ("WAC"). Vantage's actual Oncalaris® purchases consistently and substantially exceeded this threshold throughout the term of the EDA:

Amendment Requirement (Section 13.1). Section 13.1 stated: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties." This provision established a clear contractual requirement for any modification to the EDA, including any modification to the Territory defined in Exhibit A.

Governing Law (Section 14.2). The EDA was governed by the laws of the Commonwealth of Massachusetts, without regard to its principles governing conflicts of law.

Dispute Resolution (Section 14.5). Section 14.5 vested exclusive jurisdiction in the state or federal courts located in the Commonwealth of Massachusetts.

Integration Clause (Section 14.8). Section 14.8 contained a standard integration clause providing that the EDA constituted the entire agreement between the parties with respect to the subject matter thereof and superseded all prior negotiations, representations, understandings, or agreements, whether oral or written.

C. The Dispute

The dispute that gave rise to this litigation arose from Vantage's unauthorized distribution of Oncalaris® to hospitals and oncology clinics located in New York, New Jersey, and Pennsylvania (the "tri-state area") — states that were not included in the Territory as defined in Exhibit A.

Unauthorized Tri-State Distribution. On or about September 14, 2020, Vantage began shipping Oncalaris® to customers located in the tri-state area without obtaining Penterra's prior written consent as required by Section 2.3 of the EDA. Between approximately September 2020 and March 2021, Vantage generated approximately $6.4 million in revenue from these unauthorized tri-state sales. The scope and systematic nature of these shipments indicated that Vantage's expansion was not inadvertent but rather reflected a deliberate commercial strategy to extend its distribution footprint beyond the contractual Territory.

Vantage's Asserted Justification. Throughout the dispute and the subsequent litigation, Vantage advanced two principal justifications for its tri-state distribution activities:

First, Vantage contended that the January 12, 2018 email from Steven Kapoor (Penterra's VP, Commercial Operations) to Donald Farnham (the "Kapoor Email") constituted the "prior written consent" required by Section 2.3 of the EDA for Vantage to distribute Products outside the Territory. The Kapoor Email stated in its entirety:

"Don — good catching up yesterday. We're definitely open to exploring expansion into NY/NJ/PA once your New England footprint is fully ramped. Let's circle back mid-year and see where things stand."

Penterra's position — ultimately adopted by the court — was that this email merely expressed a willingness to discuss potential future expansion and did not constitute consent, authorization, or an agreement to modify the Territory. The language was conditional and aspirational ("open to exploring," "once ... fully ramped," "circle back mid-year and see where things stand"), and it was not signed by both parties as required by Section 13.1 for any amendment or modification.

Second, Vantage argued that Penterra's alleged course of dealing over three years — including Penterra's purported failure to object to certain Vantage shipments to New York customers beginning in late 2019 — had effected a de facto modification of Exhibit A, expanding the Territory to include the tri-state area. Penterra contested the factual premise of this argument and maintained that, even if Penterra had been aware of sporadic out-of-territory shipments, the written-amendment requirement of Section 13.1 and the integration clause of Section 14.8 precluded any implied modification.

Meridian Term Sheet. The dispute had significant collateral commercial consequences for Penterra. On February 15, 2021, Penterra had executed a term sheet with Meridian National Distributors, Inc. ("Meridian"), a New York corporation with offices at 520 Seventh Avenue, 12th Floor, New York, New York 10018, to distribute Oncalaris® in New York, New Jersey, Pennsylvania, and Maryland. Meridian, under the leadership of its President, Thomas Welliver, had been selected following a competitive evaluation process. However, the Meridian arrangement stalled when Vantage asserted exclusive distribution rights over the tri-state area. Resolution of the territorial dispute was therefore a commercial priority for Penterra beyond the litigation itself.

Pre-Litigation Correspondence. On March 8, 2021, Penterra's General Counsel, Jennifer Chao, sent a cease-and-desist letter to Donald Farnham, demanding that Vantage immediately cease all distribution activities in New York, New Jersey, and Pennsylvania. The letter detailed Penterra's position regarding the limited scope of the Territory under Exhibit A and the absence of any written consent or amendment authorizing tri-state distribution.

On March 22, 2021, Kenneth Rourke of HSP responded on Vantage's behalf in a letter addressed to Ms. Chao. The letter asserted that the Kapoor Email and Penterra's course of dealing had expanded the Territory and that Penterra's threat to restrict Vantage's distribution activities and engage an alternative distributor for the tri-state area constituted a breach of the EDA and tortious interference with Vantage's business relationships. The letter threatened a counterclaim seeking $35 million in damages. It was this posture — and the magnitude of the threatened exposure — that precipitated Penterra's engagement of C&H and the decision to file a preemptive declaratory-judgment action.

IV. PROCEDURAL HISTORY

A. Pre-Litigation Phase

On March 26, 2021, the Firm completed its conflict-of-interest check, which cleared the engagement with no identified conflicts. The engagement letter was executed on March 29, 2021, by Ms. Chao on behalf of Penterra and by Linda Osei on behalf of C&H.

Promptly following engagement, C&H advised Penterra to issue and distribute a litigation hold notice to key custodians within the company to ensure preservation of all potentially relevant documents and electronically stored information. The litigation hold notice was distributed internally at Penterra to the following custodians, among others: Dr. Marcus Lindholm (CEO), Jennifer Chao (General Counsel), Steven Kapoor (VP, Commercial Operations), Rachel Mendez (Director of Distribution & Logistics), and members of the distribution, logistics, and commercial operations teams who had been involved in the Vantage relationship.

During the pre-filing phase, the C&H team conducted a comprehensive analysis of the factual record and applicable law to determine the appropriate claims, forum, and litigation strategy. The team's pre-filing analysis confirmed that the dispute was ripe for declaratory relief under Massachusetts General Laws chapter 231A, given the actual and concrete controversy between the parties regarding the scope of the Territory under the EDA. The analysis further recommended that Penterra file the declaratory-judgment action proactively in the Massachusetts Superior Court, Business Litigation Session, Suffolk County, both to control the forum and to establish the litigation narrative before Vantage could file an affirmative breach-of-contract action.

B. Pleadings. April 12, 2021: Complaint. On April 12, 2021, Penterra filed its Complaint for Declaratory Judgment in the Massachusetts Superior Court, Business Litigation Session, Suffolk County. The Complaint was assigned Docket No. 2184-CV-01537-BLS. The Complaint sought a judicial declaration that the Territory under the EDA was limited to the six New England States enumerated in Exhibit A and that Vantage had no contractual right to distribute Penterra products in New York, New Jersey, or Pennsylvania.

May 14, 2021: Answer and Counterclaims. On May 14, 2021, Vantage, through HSP, filed its Answer and Counterclaims. Vantage denied the material allegations of the Complaint and asserted three counterclaims: (1) breach of contract, alleging that Penterra had breached the EDA by threatening to engage an alternative distributor for the tri-state area in contravention of Vantage's purported exclusive distribution rights; (2) breach of the implied covenant of good faith and fair dealing, alleging that Penterra had acted in bad faith by repudiating the alleged territorial expansion and threatening to terminate the relationship; and (3) promissory estoppel, alleging that the Kapoor Email constituted a clear and definite promise of territorial expansion upon which Vantage had reasonably relied to its detriment by investing in tri-state sales infrastructure and customer relationships. Vantage sought damages of $35 million across the three counterclaims.

June 4, 2021: Answer to Counterclaims. On June 4, 2021, Penterra filed its Answer to Vantage's Counterclaims, denying all material allegations and asserting affirmative defenses including the statute of frauds, the integration/merger clause (Section 14.8), the written-amendment requirement (Section 13.1), the parol evidence rule, and failure to state a claim upon which relief can be granted.

C. Case Management

June 18, 2021: Initial Case Management Conference. On June 18, 2021, an initial case management conference was held before the Honorable Diane L. Costigan, Justice of the Superior Court, Business Litigation Session. At the conference, the parties and the court established a discovery schedule, set deadlines for dispositive motions, and discussed the general posture of the case. Judge Costigan's familiarity with complex commercial disputes and her active management of the Business Litigation Session docket contributed to the efficient progression of the case through the court system.

D. Fact discovery (July 2021 – January 2022)

Fact discovery was conducted over a period of approximately six months, from July 2021 through the close of fact discovery on January 14, 2022. The key discovery events and milestones are described below.

Written discovery. On August 9, 2021, Penterra served its First Set of Interrogatories (Nos. 1–25) and First Request for Production of Documents (Nos. 1–42) on Vantage. On September 3, 2021, Vantage served its First Set of Interrogatories (Nos. 1–20) and First Request for Production of Documents (Nos. 1–38) on Penterra. Both parties responded to the opposing party's written discovery requests within the time periods established by the applicable rules, subject to certain objections and negotiations.

Penterra asserted the attorney-client privilege and the work product doctrine over certain communications between C&H attorneys and Penterra personnel, which were identified on a detailed privilege log. Vantage challenged several entries on Penterra's privilege log, particularly those relating to communications between Jennifer Chao and Steven Kapoor. Vantage argued that to the extent Chao and Kapoor were discussing the substance of the Vantage distribution relationship — rather than seeking or providing legal advice — those communications were not protected by the attorney-client privilege. This discovery dispute was resolved through a meet-and-confer process memorialized in a letter from Hannah Brinkley to Kenneth Rourke dated October 4, 2021. Following the meet-and-confer, the parties reached agreement on the scope of the privilege, and Penterra supplemented its privilege log and produced certain non-privileged communications while maintaining its privilege assertions over core attorney-client communications. No motion to compel was filed.

Depositions. Four depositions were taken during the fact discovery period:

October 18, 2021 — Donald R. Farnham. Mr. Farnham was deposed in his capacity as Vantage's Managing Member and CEO. The deposition was conducted over approximately seven hours by Hannah Brinkley, with Patrick Gallagher attending in a support role. Key admissions obtained during the Farnham deposition included: (i) Mr. Farnham acknowledged that no signed amendment to Exhibit A of the EDA was ever executed expanding the Territory to include any state beyond the six New England States; (ii) Mr. Farnham confirmed that his primary basis for believing Vantage had authorization to distribute in the tri-state area was the Kapoor Email, together with what he characterized as Penterra's "acquiescence" to Vantage's New York shipments; and (iii) Mr. Farnham conceded that no officer, director, or authorized representative of Penterra had expressly authorized tri-state shipments in writing. These concessions proved critical to the summary judgment record.

November 2, 2021 — Steven Kapoor. Mr. Kapoor was deposed by Kenneth Rourke of HSP, with Hannah Brinkley defending the deposition. Mr. Kapoor's testimony was consistent with the positions set forth in his subsequent affidavit in support of summary judgment. Specifically, Mr. Kapoor testified that his January 12, 2018 email to Donald Farnham was intended to express Penterra's general willingness to explore the possibility of future territorial expansion at some undefined point in the future, once Vantage had demonstrated full market coverage within the existing New England Territory. Mr. Kapoor was clear and consistent in his testimony that the email was not intended to constitute consent, authorization, or an agreement to expand the Territory, and that he was not authorized to unilaterally modify the terms of the EDA. The defense of the Kapoor deposition was a critical component of the litigation strategy, and Mr. Kapoor's preparation and demeanor contributed to the credibility and persuasive weight of his testimony on the summary judgment record.

November 19, 2021 — Rachel Mendez. Ms. Mendez was deposed by Alicia Fontaine of HSP, with Patrick Gallagher defending the deposition under Hannah Brinkley's supervision. Ms. Mendez testified regarding the distribution logistics framework at Penterra, including the internal systems and processes governing the routing and authorization of product shipments to distributors. Her testimony established that Penterra's distribution systems were configured to direct Oncalaris® shipments to Vantage only for delivery addresses located within the six New England States, and that no systemic or administrative changes had been made to authorize or facilitate shipments to the tri-state area through Vantage. This testimony provided important corroborating evidence that Penterra had never authorized or facilitated tri-state distribution through Vantage at the operational level.

December 7, 2021 — Brian Kopec. Mr. Kopec, Vantage's Outside Sales Director, was deposed by Hannah Brinkley. Mr. Kopec's testimony covered his role in directing Vantage's sales activities into the tri-state area, his knowledge of the territorial restrictions in the EDA, his customer contacts in New York, New Jersey, and Pennsylvania, and the approximately $6.4 million in tri-state revenue generated between September 2020 and March 2021. Mr. Kopec's testimony was generally consistent with Vantage's position but provided useful admissions regarding the systematic and deliberate nature of the tri-state expansion effort.

Close of Fact discovery. Fact discovery closed on January 14, 2022. Prior to the close of discovery, C&H obtained a stipulation from HSP — memorialized in a letter from Hannah Brinkley to Alicia Fontaine dated January 10, 2022 — regarding the authenticity and admissibility of the Kapoor Email. This stipulation streamlined the summary judgment record by eliminating any potential disputes regarding the foundation for the email's admission into evidence.

E. Summary Judgment Briefing

February 11, 2022: Penterra's Motion for Summary Judgment. On February 11, 2022, Penterra filed its Motion for Summary Judgment, accompanied by a Memorandum of Law in Support, a Statement of Undisputed Material Facts pursuant to Superior Court Rule 9A(b)(5), and supporting affidavits from Steven Kapoor and Rachel Mendez. Penterra's motion argued that the plain and unambiguous language of Exhibit A limited the Territory to the six New England States, that the Kapoor Email did not constitute "prior written consent" under Section 2.3, that no signed written amendment to Exhibit A existed as required by Section 13.1, and that Vantage's course-of-dealing argument was barred by the integration clause and the written-amendment requirement. Penterra further moved for dismissal of all three counterclaims on the grounds that they were predicated on the same failed theory of territorial expansion and, in the case of the promissory estoppel claim, failed to satisfy the elements of a clear and definite promise and reasonable reliance.

February 25, 2022: Vantage's Cross-Motion for Summary Judgment. On February 25, 2022, Vantage filed a Cross-Motion for Summary Judgment, supported by its own memorandum of law, statement of facts, and affidavits from Donald Farnham and Brian Kopec. Vantage's cross-motion argued that the Kapoor Email, read in context with the parties' course of dealing and Penterra's alleged failure to object to tri-state shipments, created a triable issue — or, alternatively, entitled Vantage to judgment as a matter of law — on whether the Territory had been expanded or Penterra had consented to extra-territorial distribution.

March 18, 2022: Penterra's Opposition and Reply. On March 18, 2022, Penterra filed its Opposition to Vantage's Cross-Motion for Summary Judgment and its Reply in Support of Penterra's Motion for Summary Judgment. The combined filing addressed each of Vantage's factual and legal arguments, emphasized the undisputed documentary record (including the absence of any signed amendment and the plain language of the written-amendment and integration clauses), and argued that the Kapoor Email's aspirational language could not, as a matter of law, constitute consent, amendment, or a clear and definite promise.

April 1, 2022: Vantage's Opposition and Reply. On April 1, 2022, Vantage filed its Opposition to Penterra's Motion for Summary Judgment and its Reply in Support of its own Cross-Motion. Vantage reiterated its arguments regarding the Kapoor Email, the course-of-dealing evidence, and the alleged reasonableness of Vantage's reliance.

Sur-Reply Analysis. Following receipt of Vantage's April 1, 2022 filing, the C&H team conducted an internal analysis on April 8, 2022, to determine whether a sur-reply was warranted. The team concluded that Vantage had raised no genuinely new arguments in its reply that had not already been addressed in Penterra's prior filings, and that a sur-reply was unnecessary and could risk diluting the strength of the existing briefing. The decision not to seek leave to file a sur-reply proved sound.

May 6, 2022: Oral Argument. On May 6, 2022, the court held oral argument on the cross-motions for summary judgment before the Honorable Diane L. Costigan. Linda Osei argued on behalf of Penterra, with Hannah Brinkley attending at counsel table. Kenneth Rourke argued on behalf of Vantage. The argument lasted approximately ninety minutes and focused primarily on the legal significance of the Kapoor Email, the enforceability of the written-amendment and integration clauses, and the viability of Vantage's promissory estoppel theory. During the argument, the court posed probing questions to both sides, and the tenor of the court's questioning suggested a focus on the contractual text and the absence of a signed amendment.

F. Decision and Judgment

July 15, 2022: Memorandum of Decision and Order. On July 15, 2022, the court issued its Memorandum of Decision and Order on the parties' cross-motions for summary judgment. The court granted Penterra's Motion for Summary Judgment in its entirety, denied Vantage's Cross-Motion for Summary Judgment, and dismissed all three of Vantage's counterclaims on the merits. The court's reasoning is summarized in detail in Section V below.

August 5, 2022: Final Judgment. On August 5, 2022, the court entered Final Judgment in accordance with its Memorandum of Decision and Order, declaring that the Territory under the EDA is limited to the six New England States enumerated in Exhibit A and that Vantage has no contractual right to distribute Penterra products in New York, New Jersey, or Pennsylvania.

G. Post-Judgment / Appeal Period

Following entry of Final Judgment on August 5, 2022, the C&H team monitored the thirty-day appeal window. Under Massachusetts Rules of Appellate Procedure, Rule 4(a), Vantage had until September 4, 2022, to file a notice of appeal with the Appeals Court. The C&H team checked the court docket regularly during this period, and no notice of appeal was filed by Vantage.

The appeal deadline expired on September 4, 2022, without any filing by Vantage. The matter is therefore fully concluded, and the court's judgment is final and non-appealable.

V. SUMMARY OF THE COURT'S DECISION

A. Holding. The court's Memorandum of Decision and Order resolved all claims and counterclaims in the case. Specifically, the court held as follows:

1. The Territory under the EDA, as defined in Exhibit A, is limited to the six New England States enumerated therein: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont. The Territory does not encompass New York, New Jersey, or Pennsylvania.

2. The Kapoor Email did not constitute "prior written consent" by Penterra under Section 2.3 of the EDA for Vantage to distribute Products outside the Territory.

3. No amendment or modification to Exhibit A was ever executed in compliance with the written-amendment requirement of Section 13.1 of the EDA.

4. Vantage's counterclaim for breach of contract is dismissed on the merits, as Penterra did not breach the EDA by restricting Vantage's distribution activities to the contractually defined Territory.

5. Vantage's counterclaim for breach of the implied covenant of good faith and fair dealing is dismissed on the merits, as Penterra's actions were consistent with the express terms of the EDA.

6. Vantage's counterclaim for promissory estoppel is dismissed on the merits, as the Kapoor Email did not constitute a clear and definite promise, and Vantage's reliance was not reasonable in light of the EDA's integration clause and written-amendment requirements.

B. Key Reasoning

The court's analysis addressed each of the principal arguments raised by the parties and rested on the following key pillars of reasoning:

Plain Language of Exhibit A. The court began its analysis with the text of Exhibit A itself, which unambiguously listed six specific states by name — Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont — as constituting the Territory. The court found that the enumeration was clear, specific, and left no room for ambiguity. There was no reference to the tri-state area, no general language suggesting regional expansion, and no catch-all provision that could be construed to encompass unlisted states. Applying settled principles of Massachusetts contract interpretation, the court concluded that where a contractual provision is clear and unambiguous on its face, it must be enforced according to its terms without resort to extrinsic evidence.

The Kapoor Email. The court devoted significant attention to the January 12, 2018 email from Steven Kapoor to Donald Farnham, which was the factual centerpiece of Vantage's defense. The court found that the email, by its plain language, did not constitute "prior written consent" under Section 2.3 of the EDA. The court emphasized the conditional and aspirational nature of the email's language: the phrase "open to exploring" expressed a willingness to discuss future possibilities, not a grant of consent or authorization; the phrase "once your New England footprint is fully ramped" imposed an unfulfilled condition that was never formally evaluated or satisfied; and the phrase "circle back mid-year and see where things stand" was an invitation for future discussion, not a present commitment. The court noted that no reasonable reading of this language could be construed as a definitive consent to expand the Territory.

Written-Amendment Requirement (Section 13.1). The court further found that, even if the Kapoor Email could somehow be construed as reflecting Penterra's informal assent to territorial expansion — which the court expressly declined to find — it would not satisfy the requirements of Section 13.1, which mandated that any amendment, modification, or waiver of the EDA must be set forth in a written instrument signed by both parties. The Kapoor Email was neither a formal instrument nor signed by both parties. Indeed, there was no evidence in the record of any signed amendment to Exhibit A ever having been executed, a fact that Vantage's CEO, Donald Farnham, conceded at his deposition.

Integration Clause (Section 14.8). The court observed that the integration clause in Section 14.8, when read in conjunction with the written-amendment requirement in Section 13.1, provided a robust contractual framework precluding oral or implied modifications to the EDA. Under Massachusetts law, such clauses are enforceable and serve to protect the integrity of written agreements against claims of informal modification or side agreements.

Course-of-Dealing Argument. The court rejected Vantage's argument that Penterra's alleged course of dealing — specifically, Penterra's purported failure to object to certain Vantage shipments to customers in New York beginning in late 2019 — had effected a modification of the Territory. The court held that, under Massachusetts law, written-modification clauses are generally enforceable and operate to bar implied oral or conduct-based modifications. The court cited Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000), in support of this proposition, noting that the Supreme Judicial Court has consistently upheld the enforceability of contractual provisions requiring amendments to be in writing. The court further observed that even if some evidence of Penterra's awareness of sporadic out-of-territory shipments existed, mere knowledge or inaction would not constitute the affirmative written consent required by the contract's own terms.

Promissory Estoppel Counterclaim. With respect to Vantage's promissory estoppel counterclaim, the court held that the claim failed for two independent reasons. First, the Kapoor Email did not constitute a "clear and definite promise" as required under Massachusetts law to support a promissory estoppel claim. The aspirational and conditional language of the email fell far short of the clarity and definiteness required. Second, even if the email could be construed as a promise, Vantage's reliance on the email as a basis for investing in tri-state distribution infrastructure was not reasonable in light of the EDA's express written-amendment requirement and integration clause. A sophisticated commercial party such as Vantage, represented at all relevant times by experienced counsel, could not reasonably claim to have relied on an informal email as a substitute for a formal contractual amendment.

C. Outcome Assessment

The court's decision constituted a complete victory for Penterra on all claims and counterclaims. Penterra's declaratory-judgment claim was fully vindicated, and the court's declaration established with finality that the Territory under the EDA is limited to the six New England States enumerated in Exhibit A. This declaration resolved the uncertainty that had clouded Penterra's ability to engage alternative distributors in the tri-state area and eliminated the risk that Vantage could assert exclusive distribution rights beyond the contractual Territory.

Equally important, the dismissal of all three of Vantage's counterclaims eliminated $35 million in potential damages exposure. This was a significant outcome given the magnitude of the threatened exposure and the aggressive posture adopted by Vantage and its counsel throughout the litigation.

As a practical matter, the court's ruling freed Penterra to proceed with the finalization of its distribution arrangement with Meridian National Distributors, Inc. for the distribution of Oncalaris® in the tri-state area (New York, New Jersey, and Pennsylvania) and Maryland. The resolution of the Vantage dispute removed the principal impediment to the Meridian arrangement and enabled Penterra to resume its commercial expansion strategy for its flagship oncology product.

VI. FINANCIAL SUMMARY

A. Professional Fees

Total professional fees billed to the Client over the course of the engagement were $894,320.00 (after application of the 7% discount). This figure represents the aggregate of all billable hours recorded by the engagement team at their respective discounted rates throughout the life of the matter, from the initial engagement in March 2021 through the completion of post-judgment monitoring activities in September 2022. It bears noting that the pre-discount aggregate of professional fees would have been materially higher; the 7% discount reflects the Firm's longstanding relationship with Penterra and was applied consistently across all invoices rendered during the engagement.

B. Costs and Disbursements

Total costs and disbursements incurred in connection with the matter were $47,615.00. These costs encompassed the following principal categories:

• Court filing fees

• Deposition transcript costs (four depositions, including expedited transcript delivery)

• Travel expenses (principally for depositions and the oral argument hearing)

• Service of process fees

• Copying, printing, and document production costs

• Miscellaneous costs (including courier services, postage, and court-related administrative expenses)

All costs and disbursements were incurred in the ordinary course of the litigation and are consistent with the categories identified in the engagement letter.

C. Aggregate Amount Billed

The total amount billed to the Client across all invoices for the engagement was $941,935.00, comprising $894,320.00 in professional fees and $47,615.00 in costs and disbursements. This aggregate amount came in below the midpoint of the $750,000 to $1,200,000 estimated budget range that was communicated to the Client at the outset of the engagement, reflecting the efficient resolution of the matter on summary judgment without the need for trial preparation, witness marshaling, or a multi-day trial.

The final invoice for the matter was transmitted by Priya Anand to Jennifer Chao on August 10, 2022, and all invoices have been paid in full by Penterra.

D. Budget Comparison

The following table summarizes the comparison between the estimated budget and actual costs:

The primary driver of the favorable budget outcome was the resolution of the matter at the summary judgment stage. Had the case proceeded to trial, the Firm estimated that additional costs of approximately $200,000 to $350,000 would have been incurred for trial preparation (including preparation of fact and potential expert witnesses, preparation of trial exhibits, pre-trial motions, and jury instructions), together with trial-period attorney time and associated costs for a proceeding estimated at five to seven trial days. The successful resolution on summary judgment eliminated these costs entirely and delivered a favorable result for the Client at a materially lower overall expenditure than had been budgeted for a trial scenario.

VII. KEY LESSONS LEARNED

This section identifies key lessons and practice points arising from the engagement that may be of use to the Firm and to the Client in future matters. These observations are drawn from the substantive legal issues presented, the litigation strategy employed, and the practical dynamics of the case.

A. Enforceability of Written-Modification Clauses Under Massachusetts Law

The court's decision confirmed that Massachusetts courts consistently enforce contractual provisions requiring amendments to be in writing and signed by both parties, consistent with the holding of the Supreme Judicial Court in Cambridge Biotech Corp. v. Pasteur Falveris Diagnostics, 433 Mass. 122 (2000). Written-modification clauses such as Section 13.1 of the EDA serve as powerful defensive tools against claims of oral modification or modification by course of dealing. They provide contracting parties with a clear, enforceable mechanism for ensuring that the terms of their agreements cannot be altered without mutual, documented consent.

For future client counseling purposes, the Firm should continue to recommend that written-amendment clauses be clearly drafted, broadly worded, and prominently positioned within commercial agreements. In addition, client personnel — particularly those involved in day-to-day commercial relationships with counterparties — should be trained on the significance of these clauses and the importance of refraining from informal representations that could be misconstrued as consent or waivers.

B. Importance of Precise Territory Definitions

The clarity and specificity of Exhibit A was dispositive in this case. Because the Territory was defined by reference to six specifically enumerated states, the court had no difficulty concluding that the Territory was unambiguous and that it did not include any unlisted states. This precision eliminated any basis for Vantage to argue that the Territory was ambiguous or that extrinsic evidence was admissible to expand its scope.

As a best practice for distribution agreements, the Firm should advise clients to define territories by specific enumeration (e.g., by naming individual states, counties, or ZIP codes) rather than by reference to regions, geographies, or other potentially ambiguous descriptors (e.g., "the Northeast" or "the New England area"). While regional references may seem convenient, they can introduce ambiguity that creates litigation risk. In this case, the specificity of Exhibit A was the single most important factor in Penterra's favor.

C. Email Communications as a Risk Factor

The Kapoor Email was the factual centerpiece of the litigation. Although the court ultimately found that the email was insufficient to constitute consent, authorization, or a promise, the email created significant litigation risk and was the primary basis on which Vantage justified its tri-state distribution activities and its counterclaims. The aspirational language used by Mr. Kapoor — "open to exploring," "circle back mid-year" — while ultimately insufficient to modify the EDA, was sufficiently forward-looking and affirmative in tone that it provided Vantage with a colorable (if ultimately unsuccessful) basis for its position.

The lesson for clients is clear: commercial teams must be trained on the legal significance of informal email communications, particularly in the context of distribution agreements and other commercial arrangements with defined amendment procedures. Employees should understand that emails can be — and frequently are — used as evidence in litigation to support claims of modification, waiver, or estoppel. Even language intended as aspirational or preliminary can take on unintended legal significance when read out of context. The Firm should recommend that Penterra (and similarly situated clients) implement periodic training programs for commercial operations personnel on best practices for email communications with distribution partners, including the importance of including disclaimers or clarifying language when discussing potential future changes to contractual terms.

D. Integration Clauses as Litigation Shields

Section 14.8 of the EDA — the integration clause — functioned effectively alongside Section 13.1 (the written-amendment requirement) to prevent Vantage from introducing extrinsic evidence of alleged oral or implied modifications to the EDA. The combination of these two provisions created a formidable contractual barrier to Vantage's claims.

As a drafting best practice, integration clauses should be broadly worded and paired with written-amendment requirements for maximum protective effect. The two provisions operate synergistically: the integration clause establishes that the written contract is the parties' complete and final agreement, while the written-amendment clause ensures that any changes to that agreement must be documented with the same formality. Together, they provide a comprehensive defense against claims of informal modification, side agreements, or course-of-dealing-based changes.

E. Value of Early Declaratory-Judgment Filing

The decision to file the declaratory-judgment action proactively — before Vantage could file an affirmative breach-of-contract suit — proved to be a sound strategic choice. By filing first, Penterra was able to control the litigation narrative, frame the dispute as a contract-interpretation issue (rather than a breach-of-contract claim), and choose the forum. The Business Litigation Session in Suffolk County, Massachusetts, proved to be an efficient and well-suited forum for this commercial contract dispute, offering a judge with experience in complex business litigation and a streamlined case management process.

Penterra's proactive posture also allowed it to set the pace of the litigation. By moving quickly to file the complaint, initiate discovery, and seek summary judgment, the C&H team maintained the initiative throughout the case and drove the matter to resolution within approximately sixteen months of filing — a timeline that was favorable to the Client given the complexity of the issues and the magnitude of Vantage's threatened counterclaims.

F. Deposition Strategy

The deposition strategy employed in this matter contributed significantly to the successful summary judgment outcome. Three aspects merit particular note:

First, the key concessions obtained during the Farnham deposition — including Mr. Farnham's admissions that no signed amendment to Exhibit A was ever executed and that no Penterra officer expressly authorized tri-state shipments in writing — were critical to establishing the undisputed factual record that supported summary judgment. Careful preparation and targeted questioning allowed the C&H team to elicit these admissions clearly and unambiguously.

Second, the defense of the Kapoor deposition was a high-stakes exercise that required extensive preparation. Mr. Kapoor was the author of the email at the center of the dispute, and any damaging testimony regarding his intent or the email's meaning could have undermined Penterra's position. Through thorough preparation sessions and careful attention to deposition protocol, the C&H team ensured that Mr. Kapoor's testimony was consistent, credible, and supportive of Penterra's interpretation of the email as aspirational and non-binding.

Third, the Mendez deposition provided valuable corroborating evidence at the operational level. Ms. Mendez's testimony regarding Penterra's logistics systems — specifically, that the systems were configured to direct Oncalaris® shipments to Vantage only for delivery addresses within the New England Territory — reinforced Penterra's position that it had never authorized or facilitated tri-state distribution through Vantage. This operational evidence complemented the contractual analysis and strengthened the overall summary judgment record.

VIII. RECOMMENDATIONS FOR FILE RETENTION AND CLOSING

A. File Retention

All physical and electronic files associated with matter number 1018-00007 should be retained in accordance with Calderwood & Harkness LLP's standard document retention policy. Consistent with the Firm's policy for concluded litigation matters, the minimum retention period for this matter shall be ten (10) years from the date of matter closing — i.e., through September 2032 at the earliest.

The client file contains materials protected by the attorney-client privilege and the work product doctrine, including internal memoranda, legal research, draft filings, strategy communications, and other privileged materials. Appropriate access controls should be maintained on all physical and electronic files to prevent inadvertent disclosure or unauthorized access.

The following categories of documents should be separately indexed and flagged within the file for ease of future reference:

• Pleadings, motions, and briefs filed in the action

• Court orders, including the Memorandum of Decision and Order dated July 15, 2022, and the Final Judgment dated August 5, 2022

• The executed Exclusive Distribution Agreement and all exhibits thereto (including Exhibit A)

• The Kapoor Email (January 12, 2018)

• Deposition transcripts (Farnham, Kapoor, Mendez, Kopec)

• Affidavits submitted in connection with summary judgment

• Key correspondence between the parties and between counsel

• This Matter Closing Memorandum

B. Client File Return

Hannah Brinkley or Patrick Gallagher should confirm with Jennifer Chao at Penterra whether the Client requires the return of any original documents that were provided to the Firm during the engagement. To the extent that original documents were provided and are no longer needed by the Firm for retention purposes, they should be returned to the Client promptly upon request.

Regardless of whether original documents are requested, the Firm should provide Penterra's legal department with electronic copies of the complete court docket, all filed pleadings and submissions, and the court's Memorandum of Decision and Order and Final Judgment. These materials constitute the core court record and are appropriately shared with the Client for its own files.

C. Closing Administrative Steps

The following administrative steps should be completed in connection with the formal closing of the matter:

1. Billing and Conflicts System. The matter status in the Firm's billing and conflicts management system should be changed from "Active" to "Closed" effective as of the date of this memorandum. The closing date should be recorded as September 12, 2022.

2. Invoice Confirmation. Confirm that all invoices rendered in connection with this matter have been paid in full by the Client. The final invoice, dated August 10, 2022, was transmitted by Priya Anand to Jennifer Chao. As of the date of this memorandum, no outstanding balances remain.

3. Case Tracking and Calendaring. Remove the matter from all active case tracking lists, calendaring systems, and court deadline monitoring databases maintained by the Firm. No further deadlines or filings are anticipated.

4. Experience Database. Update the Firm's internal experience and matter database to reflect the successful outcome of this engagement. The database entry should include the following key descriptors: declaratory judgment granted on summary judgment; all counterclaims dismissed; Massachusetts contract interpretation; pharmaceutical distribution; exclusive distribution agreement; territory dispute; written-amendment clause; integration clause; Business Litigation Session. This information will be valuable for future pitch materials, client development, and cross-selling opportunities within the Firm's life sciences and commercial litigation practices.

D. Potential Future Matters

Although this matter is fully concluded, several commercial and legal issues may give rise to future work for Penterra. The engagement team notes the following:

First, the EDA's original five-year term expired on June 30, 2022 — approximately two weeks before the court issued its Memorandum of Decision and Order. The court's ruling provides important clarity regarding the scope of the Territory under the EDA, which will be relevant to any future dealings between Penterra and Vantage, including any potential renewal, renegotiation, or termination of the distribution relationship for the New England territory.

Second, with the territorial dispute resolved, Penterra may now seek counsel regarding the finalization of its distribution arrangement with Meridian National Distributors, Inc. for the distribution of Oncalaris® in the tri-state area and Maryland. The term sheet with Meridian was executed in February 2021, and the transaction has been on hold pending the resolution of this litigation. Penterra may wish to engage C&H or another firm to assist with the negotiation and execution of a definitive distribution agreement with Meridian.

Third, Penterra may wish to evaluate the status of its ongoing relationship with Vantage in the New England territory, including whether to exercise the non-renewal option under the EDA's auto-renewal provisions or to renegotiate the terms of the distribution relationship. Given the litigation history, Penterra may benefit from counsel's guidance on managing the commercial dynamics of this relationship going forward.

Fourth, while no new claims by Vantage are anticipated given the court's comprehensive ruling dismissing all counterclaims on the merits — and given the expiration of the appeal period without a filing — the Firm should remain alert to any unanticipated developments and should be available to advise Penterra if any new issues arise.

The engagement team recommends that it remain available to advise Penterra on these related commercial matters if and when requested by the Client.

IX. APPROVALS AND SIGN-OFF

This Matter Closing Memorandum has been prepared by the undersigned Lead Associate and is submitted to the Responsible Partner for review and approval. Upon approval, the matter will be formally closed in accordance with the Firm's policies and procedures.

PREPARED BY:

________________________________________

Hannah Brinkley Lead Associate, Litigation Calderwood & Harkness LLP

Date: ________

REVIEWED AND APPROVED BY: